 This is an open-label, multi-center, sequential groups, dose escalation study of TAB08 in patients with metastatic or unresectable advanced solid malignancies. The study will consist of 2 parts: a dose-escalation part with a standard 33 design, followed by a dose-expansion part once the maximum tolerated dose MTD has been determined. 